Navigation Links
Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
Date:1/16/2008

MENLO PARK, Calif., Jan. 16 /PRNewswire/ -- Fundamental Applied Biology, Inc. (FAB) announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase IIB grant from the National Science Foundation. The $500,000 grant will be used to continue to develop FAB's cell-free protein synthesis technology towards commercialization.

During Small Business Technology Transfer (STTR) Phase I and Phase II NSF projects, FAB successfully demonstrated that certain proteins could be made in a cell-free system in a soluble form, in a controllable and efficient fashion. With the Phase IIb grant, FAB will continue to develop the technology with a market-driven, therapeutic protein as FAB's first target product.

"We are pleased to receive this grant from the NSF," said Daniel S. Gold, PhD, CEO of FAB. "The grant will allow FAB to further develop and optimize our cell-free technology to enable the production of pharmaceutical protein therapeutics with the goal of improving their biological activity."

"This grant reflects NSF's continued interest in the commercialization potential of cell-free technology. The STTR Phase I and II grants were instrumental in supporting FAB's research initiatives to develop marketable biologics as a continuation of work initiated in my laboratory at the Department of Chemical Engineering at Stanford University," noted Professor James Swartz, D.Sc.

Intact organisms which have the limitation of having to maintain their own viability can have difficulty making toxic or difficult to fold proteins. Cell-free technology was designed to overcome these limitations.

About Fundamental Applied Biology

Fundamental Applied Biology (FAB), Inc. is creating opportunities for the development of novel protein-based therapeutics and vaccines using a proprietary cell-free protein synthesis technology. Cell-free technology has the potential to overcome many of the significant limitations associated with using whole mammalian and bacterial cells for making protein-based biologics. FAB's goal is to become the leader in the field of cell-free protein synthesis by developing its own and collaborative therapies that will provide improved clinical outcomes for patients.

Contact:

Patricia Sinatra

VP, Business Development and Commercial Strategy

Fundamental Applied Biology, Inc.

(650) 329-9374

psinatra@cellfree.com

http://www.cellfree.com


'/>"/>
SOURCE Fundamental Applied Biology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndicom SpineConnect Web Platform Chosen for Applied Spines Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilization System
2. DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
3. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
4. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
5. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
6. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
7. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
8. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
9. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
10. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
11. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... 2016 According to the 2016 ... driving ambulatory blood pressure monitoring system market growth. With ... ability to respond to different pressure rates, leading to ... to various cardiovascular disorders such as heart failure, stroke, ... are growing in prevalence each year. WHO estimates that ...
(Date:5/26/2016)... May 26, 2016 According to a ... Management Market - U.S. Industry Analysis, Size, Share, Growth, Trends, ... in the U.S. was valued at US$ 5.89 Bn in ... 3.4% from 2015 to 2023 to reach US$ 7.99 Bn ... current and emerging needle free drug delivery devices and the ...
(Date:5/25/2016)... -- FDA 510(k) clearance covers Confocal ... urological and surgical applications Mauna Kea ... the multidisciplinary confocal laser endomicroscopy (CLE) platform, today ... with the 12 th 510(k) clearance from ... new FDA clearance covers Confocal Miniprobes indicated for ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... To ... solutions to the healthcare industry, The University of Scranton is adding a Certificate ... path to a career in rapidly growing field of healthcare information. , ...
(Date:5/30/2016)... ... May 30, 2016 , ... As the CDC relaxes its ... and their efforts to keep their households lice free. , According to a ... new policies that keep kids in the classroom despite the fact that they may ...
(Date:5/30/2016)... ... 30, 2016 , ... Shaolin Institute officially starts the annual ... intensive summer training camp starts on June 17th on Shaolin Institute Atlanta Campus. ... a fun and unique experience with an opportunity to learn KungFu martial arts ...
(Date:5/29/2016)... ... May 29, 2016 , ... Whole Health Supply is happy to announce ... clipper is available to the public. This is an unusual clipper because it opens ... average clipper. , Everything about this product is concentrated on ease of use, functionality ...
(Date:5/28/2016)... Aliso Viejo, California (PRWEB) , ... May 28, 2016 , ... ... just need to drag and drop a preset onto their media," said Christina Austin ... from Pixel Film Studios, editors can quickly and easily add stylish color grades to ...
Breaking Medicine News(10 mins):